suPARnostic

SEMAL_Biological clocks_Jesper Eugen - Olsen_PhD

Tue, 25 Nov 2025 15:10:21 GMT

The treaTBest study

Wed, 22 Oct 2025 14:29:04 GMT

Dr. Jesper Eugen-Olsen talks on suPAR and Chronic inflammation

Tue, 16 Jul 2024 10:41:27 GMT

Dr Eugen-Olsen talks on chronic inflammation and how it is linked to the development of disease. The lecture is from the Longevity and Biohacking Conference in Andorra, July 2024 and is named "Cracking the longevity code: Measuring and mastering chronic inflammation"

suPAR_ Causal or associated_.mp4

Tue, 15 Nov 2022 10:46:51 GMT

suPAR - A biomarker for Triage based on chronic inflammationand patient...

Fri, 10 Jun 2022 09:41:06 GMT

The Save More study

Fri, 03 Dec 2021 10:22:15 GMT

Study: suPAR Cut-Offs for Risk Stratification in Patients with Symptoms of...

Thu, 18 Nov 2021 15:12:59 GMT

This observational cohort study of 386 patients presenting symptoms of COVID-19 at the Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020, found suPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) can predict the need for mechanical ventilation and mortality in patients with COVID-19 symptoms.

suPAR can predict the need for mechanical ventilation and mortality in...

Fri, 24 Sep 2021 12:16:48 GMT

Jesper Eugen-Olsen presenting how suPAR can be used to predict patient outcomes in COVID-19 using suPAR. Read the full peer-reviewed publications: https://journals.sagepub.com/doi/full/10.1177/11772719211034685 ; https://www.researchsquare.com/article/rs-542503/v1 ; https://www.nature.com/articles/s41591-021-01499-z

Predicting patient outcomes in COVID-19

Fri, 24 Sep 2021 11:56:15 GMT

Jesper Eugen-Olsen presenting how suPAR can be used to predict patient outcomes in COVID-19 using suPAR. Read the full publication in Nature medicine here: https://www.nature.com/articles/s41591-021-01499-z

Prof. Peter Rossing on diabetes complications

Wed, 03 Jul 2019 12:53:40 GMT

Patients with type 1 diabetes are prone to develop complications such as kidney or heart disease. Professor Peter Rossing and his group are working on biomarkers that may predict which patients are in risk of developing these complications. Peter talks about their latest work on the risk biomarker suPAR and its predictive abilities. Their study "Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes" were published in Diabetes Care in 2019 (https://care.diabetesjournals.org/content/42/6/1112.long)

Interview with first author Viktor Curovic on his work on suPAR in diabetes...

Tue, 25 Jun 2019 14:28:33 GMT

interview on the following publication:

Diabetes Care. 2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V1, Theilade S2, Winther SA2, Tofte N2, Eugen-Olsen J3, Persson F2, Hansen TW2, Jeppesen J4,5, Rossing P2,5.
Author information
Abstract
OBJECTIVE:
RESEARCH DESIGN AND METHODS:
RESULTS:
CONCLUSIONS:

Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR's predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.

We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.

Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001), 1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P = 0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001).

In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.

Live fra tarmen

Fri, 02 Nov 2018 14:48:51 GMT

suPAR ca 1:10

Routine use of suPARnostic in the Emergency Department

Wed, 15 Nov 2017 14:48:58 GMT

At Copenhagen University Hospital Hvidovre, suPAR is measured as part of the routine biomarkers. suPAR is used as support for the decision to admit or discharge the acute medical patient. For more info on the suPARnostic products, please go to Virogates.com

suPAR english speak

Tue, 26 Apr 2016 15:45:35 GMT

suPAR is a biomarker on disease severity and prognosis. suPAR has been implemented in routine use at the Emergency Department at Copenhagen University Hospital Hvidovre. This movie gives insight into the clincial use of the suPAR biomarker.

suPAR - From basic research to routine clinical use - Danish speak

Sun, 10 Apr 2016 20:54:55 GMT

suPAR is today a routine marker used for accessing disease severity and prognosis in the Emergency Department. The movie is produced by Copenhagen University Hodpital Hvidovre. Photo and edit Peter Bak

Forskning på et Akut hospital - Hvidovre, suPAR og AHA - Dansk

Thu, 03 Mar 2016 10:08:36 GMT

På Hvidovre-Amager Hospital forskes i forbedring af patient behandling. To af spydspids projekterne fremhæves her, suPAR projektet som bidrager til at blive klogere på hvor syg patienten egentligt er, samt AHA projektet hvor tværfagligt samarbejde bidrager til bedre behandling og bedre overlevelse for mave-tarm patienter

suPAR and BluSense

Wed, 09 Dec 2015 11:21:17 GMT

A short film on the collaboration betwen DTU Nanotech, Copenhagen University Hospital Hvidovre, ViroGates and BluSense. Filmen er produceret af Christoffer Thinggaard og Lars Brückner.

Jesper Eugen-Olsen fortæller om suPAR

Tue, 04 Aug 2015 14:09:19 GMT

Klippet indgik i "Live fra tarmen" produceret af DR/ Lars Ostenfeld

Hvidovre Hospital - why we have implemented suPAR in clinical routine

Thu, 09 Jul 2015 14:24:23 GMT

In this movie, the Vice President, MD, Dm.Sc Torben Mogensen and the Hospital Research Director, MD, PhD Ove Andersen explains why suPAR has been implemented in routine use in the Emergency Department.

suPARnostic Quick Triage Test Instruction Video

Wed, 17 Jun 2015 09:02:43 GMT

Instruction video for the quantitation of suPAR in plasma using the Quick Triage test. The test is based on the lateral flow principle and quantifies the patient plasma suPAR value (The new updated quantitative Quick triage test). The time from plasma sample to final result is about 24 minutes. The suPARnostic Quick Triage Test is produced by ViroGates, Denmark. More information on suPAR measuring products can be found at www.suPARnostic.com

Overview of the 5'th International suPAR symposium

Fri, 25 Jul 2014 14:38:49 GMT

The 5th suPAR symposium was hosted by Prof. Markus Schultz and held at the Amsterdam Medical Center in May 2014. New and recently published data were presented and gave insights into the clinical use of suPAR. This years focus was on the use of suPAR as a risk triage marker in the Acute Medical Department. Data from the routine use as well research data complemented into a conclusion that suPAR helps changing the clinical decision. Should the patient be admitted? Sent home? Rushed to the ICU? This and more was discussed by almost 100 clinicians and researchers over the 2-day seminar.

suPAR Acute Care Triage marker at ESOF, Copenhagen 2014

Tue, 15 Jul 2014 14:57:15 GMT

In June 2014, The European Science Open Festival was held in Copenhagen, Denmark. Jesper Eugen-Olsen and Jakob Knudsen presented the suPARnostic® Quick Triage system for quick determination of the plasma suPAR level. The product is developed by the Danish company ViroGates A/S. For more info, please visit www.ViroGates.com

Dr. August Wrotek talks on suPAR as marker of severity of pneumonia in children

Fri, 13 Jun 2014 11:43:12 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Wrotek's presentation was one of 25 lectures given over the 2-day 5'th International suPAR symposium. The programme and info on the conference can be found here: www.ViroGates.com

Dr. Rafal Wlazel talks on suPAR and prediction of AMI in pPCI patients

Fri, 13 Jun 2014 11:41:26 GMT

Dr. Simone Theilade talks on suPAR as marker of diabetes complications

Fri, 13 Jun 2014 11:05:16 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Theilade's presentation was one of 25 lectures given over the 2-day 5'th International suPAR symposium. The programme and info on the conference can be found here: www.ViroGates.com

Dr. Martin Höenigl talks on suPAR and risk stratification in the Acute care...

Fri, 13 Jun 2014 10:47:56 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Höenigll's presentation was one of 25 lectures given over the 2-day Internationl suPAR symposium and The groups work was published in Journal of Internal Medicine in 2014 (http://www.ncbi.nlm.nih.gov/pubmed/24645798) and was accompaigned by an editorial (http://www.ncbi.nlm.nih.gov/pubmed/24734882).

5'th International suPAR symposium, Amsterdam May 8-9th, 2014

Sat, 29 Mar 2014 11:18:41 GMT

The 5th International suPAR symposium is hosted by Professor Marcus Schultz from The Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam.
This years theme is "suPAR and its value in clinical use". Information on Programme, registration and accommodation can be found here: http://suparnostic.com/index.php/events/supar-symposias/5th-international-supar-symposium

4th International suPAR symposium Overview

Wed, 20 Nov 2013 16:13:27 GMT

Almost 100 researchers met to present new data and discuss the potential of the suPAR biomarker in triage in the emergency room and ICU setting.

The 4th International suPAR symposium was held in late February in 2013 in Aachen, Germany.

This years suPAR symposium was entitled ” New Horizons for suPAR: Risk Stratification, Organ Dysfunction and Relevance for Specific Diseases”.

Almost 100 researchers from all over the world met to discuss the potential use of the prognostic biomarker suPAR.

The symposium was hosted by Professor Frank Tacke and Dr Alexander Koch from Aachen University Hospital

The talks started with insights into suPAR biology and pathology with ”state of the art lecture” given by professor Jochen Reiser from Chicago on the causative effect of suPAR in kidney diseases. This was followed by an overview on suPAR in Kidney diseases, liver diseases and finally in pulmonary diseases.

The overviews were followed by presentations on exciting new data on suPAR in liver cirrhosis – where does suPAR come from, how is it regulated, what is its prognostic relevance?

Hereafter chief Physician Jyrki Tenhunen gave an overview on the large amount of data published within the last year with emphesis on sepsis

Finally, on day 1, new data on suPAR and its prognostic value in Inflammatory and Infectious Diseases and Sepsis were presented and the Usefulness of suPAR in Risk Stratification of Patients with sepsis Admitted to the Emergency Department were discussed

As the day turned into night, the researchers met to socialize and exchange ideas at the suPARTY.

On day 2, after some black coffee, the researchers presented data and discussed how biomarkers may aid in clinical decision making – in particular in sepsis, Cardiology, Kidney failure, liver failure and finally in cancer.The last session gave insight into the use of suPAR as a marker of triaging in the emergency department. And Katia Donadello closed the symposium with a presentation on the potential use of suPAR in the intensive care unit.

The 4'th International suPAR symposium overview

Tue, 21 May 2013 18:55:50 GMT

Almost 100 researchers met to present new data and discuss the potential of the suPAR biomarker in triage in the emergency room and ICU setting.

The 4th International suPAR symposium was held in late February in 2013 in Aachen, Germany.

This years suPAR symposium was entitled ” New Horizons for suPAR: Risk Stratification, Organ Dysfunction and Relevance for Specific Diseases”.

Almost 100 researchers from all over the world met to discuss the potential use of the prognostic biomarker suPAR.

The symposium was hosted by Professor Frank Tacke and Dr Alexander Koch from Aachen University Hospital

The talks started with insights into suPAR biology and pathology with ”state of the art lecture” given by professor Jochen Reiser from Chicago on the causative effect of suPAR in kidney diseases. This was followed by an overview on suPAR in Kidney diseases, liver diseases and finally in pulmonary diseases.

The overviews were followed by presentations on exciting new data on suPAR in liver cirrhosis – where does suPAR come from, how is it regulated, what is its prognostic relevance?

Following this, new data on the role of suPAR in low-grade inflammation, Atherosclerosis and Life Style Diseases were presented and discussed and approximately half of the attendees had their blood drawn for suPAR measurement

Hereafter chief Physician Jyrki Tenhunen gave an overview on the large amount of data published within the last year with emphesis on sepsis

As the day turned into night, the researchers met to socialize and exchange ideas at the suPARTY.

suPAR and its prognostic properties in emergency department and intensive...

Tue, 21 May 2013 16:52:55 GMT

Katia Donadello reviews the data on suPAR in the emergency unit and in the critical care setting. This video was recorded on Tuesday the 26th of February 2013

suPAR og autoimmun sygdom - Folketinget 2009

Tue, 21 May 2013 15:51:32 GMT

Jesper Eugen-Olsen talks on autoimmunity and immune activation at the Danish Parliament 2009

From 1st to 4th suPAR symposium - What have we learned?

Tue, 21 May 2013 15:46:02 GMT

suPAR researcher Jesper Eugen-Olsen gives an overview of the suPAR data generated during the symposiums.

Professor Jørgen Jeppesen talks on low-grade inflammation and metabolic...

Fri, 22 Mar 2013 23:48:32 GMT

At the 4th International suPAR symposium, Professor, MD, Dmsc, Jørgen Jeppesen talks on how suPAR and CRP are differentially related to inflammation and metabolic syndrome

Dr. Tenhunen at the 4th International suPAR symposium

Wed, 20 Mar 2013 10:50:40 GMT

Thomas Haupt presents data on suPAR in the emergency room

Wed, 20 Mar 2013 10:47:43 GMT

At the 4th International suPAR symposium in Aachen Germany, Dr Haupt presents his data which was also recently published in critical care.

Marcus Schultz at the 4th International suPAR symposium

Tue, 19 Mar 2013 14:28:55 GMT

suPAR and APACHE II score in risk assesment in critically ill patients by Dr...

Tue, 14 Aug 2012 11:58:51 GMT

Dr Evangelos Giamarellos-Bourboulis talks on the combined use of suPAR and APACHE II score in risk assesment in critically ill patients. The work by Giamarellos-Bourboulis and coworkes was published August 8th, 2012 in Critical Care and entitled "Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor" and can be read here http://ccforum.com/content/16/4/R149/abstract

Teaser for the 4th International suPAR symposium, 2013

Wed, 18 Jul 2012 21:20:17 GMT

The 4th International suPAR symposium will be hosted by Drs. Frank Tacke and Alexander Koch from Aachen University Hospital in Germany. The symposium will be held at the super C building in Aachen on the 25-26th of February 2013.

suPAR as a prognostic biomarker in the acute care setting

Tue, 05 Jun 2012 21:01:45 GMT

A simple suPAR measurement has similar or better predictive value of mortality than SOFA score (sequential organ failure assessment score), a sepsis mortality risk algorithm including multiple laboratory and clinical measures. This and other aspects of the use of suPAR in an acute care setting was discussed at the 2nd International suPAR symposium in Copenhagen, Denmark 2011

The crystal ball biomarker - is your life killing you?

Tue, 05 Jun 2012 20:55:49 GMT

The suPAR molecule and its predictive value and role as a life style and risk biomarker is discussed at the second international suPAR symposium in Copenhagen 2011

Frank Tacke, MD, PhD, University Hopsital Achen, Germany: Diagnostic and...

Tue, 11 Oct 2011 12:48:22 GMT

Dr Tacke discuss suPAR results at the 2’nd International suPAR Symposium

Crit Care. 2011;15(1):R63. Epub 2011 Feb 16.
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F.
SourceDepartment of Medicine III, RWTH-University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.

Abstract
INTRODUCTION: suPAR is the soluble form of the urokinase plasminogen activator receptor (uPAR), which is expressed in various immunologically active cells. High suPAR serum concentrations are suggested to reflect the activation of the immune system in circumstances of inflammation and infection, and have been associated with increased mortality in different populations of non-intensive care patients. In this study we sequentially analyzed suPAR serum concentrations within the first week of intensive care in a large cohort of well characterized intensive care unit (ICU) patients, in order to investigate potential regulatory mechanisms and evaluate the prognostic significance in critically ill patients.

METHODS: A total of 273 patients (197 with sepsis, 76 without sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU), on Day 3 and Day 7, and compared to 43 healthy controls. Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed. Patients were followed for approximately one year.

RESULTS: Upon admission to the ICU suPAR serum concentrations were elevated in critically ill patients as compared with healthy controls. In sepsis patients suPAR levels were higher than in non-sepsis patients (with or without systemic inflammatory response syndrome (SIRS)). During the first week after admission to the ICU serum suPAR concentrations remained stably elevated. suPAR serum concentrations measured upon admission were closely and independently correlated to various laboratory parameters, specifically biomarkers of inflammation (tumor necrosis factor (TNF), C-reactive protein (CRP)), hepatic and renal dysfunction. High suPAR levels at admission and at Day 3 were a strong independent predictor for both ICU and long-term mortality in critically ill patients.

CONCLUSIONS: In sepsis and non-sepsis patients suPAR serum concentrations are increased upon admission to the ICU, likely reflecting the activation state of the immune system, and remain stably elevated in the initial course of treatment. Low suPAR levels are a positive predictor of ICU- and overall survival in critically ill patients, including sepsis and non-sepsis patients. Aside from its value as a promising new prognostic biomarker, both experimental and clinical studies are required in order to understand the specific effects and regulatory mechanisms of suPAR in SIRS and sepsis, and may reveal new therapeutic options.

Officel welcome words at the conference:
Dear Colleagues

On behalf of the scientific committee, it is my pleasure to welcome you to “The 2nd International Conference on suPAR” taking place in early spring 2011 at the Danish National Museum in Copenhagen.

The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.

But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do.

A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker.

We look forward to sharing these exciting data and to welcome you to the heart of Copenhagen

Sincerely

Jesper Eugen-Olsen, PhD, conference chairman
Laboratory research director,
Copenhagen University Hospital, Hvidovre

Purpose and Scope

The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.

The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will:

◦Provide a forum to learn about new findings and current suPAR studies
◦Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker
◦Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements
◦Facilitate foundation for international net-working

suPAR - the inflammatory biomarker that provides unique prognostic evidence

Tue, 11 Oct 2011 11:13:18 GMT

A short movie on suPAR

To read more on suPAR, click here:
http://chronopause.com/index.php/2011/07/14/supar-power-a-rapid-inexpensive-highly-accurate-method-of-predicting-all-cause-and-disease-specific-mortality/

Or search www.pubmed.com using keyword suPAR

17-02-2020

Tue, 11 Oct 2011 09:13:18 GMT

A short movie on suPAR

To read more on suPAR, click here:

http://chronopause.com/index.php/2011/07/14/supar-power-a-rapid-inexpensive-highly-accurate-method-of-predicting-all-cause-and-disease-specific-mortality/

Or search www.pubmed.com using keyword suPAR

suPAR and HIV infection by Dr Ostrowski - Part 2

Fri, 30 Sep 2011 14:03:01 GMT

MD, PhD, DmSc Sisse Ostrowski gives insight into the inflammatory biomarker suPAR in HIV pathogenesis. Dr Ostrowski has published several papers in the field and gives and overview of the published data at the 2nd suPAR symposium in Copenhagen in 2011

Elevated suPAR and increased risk of lung cancer in healthy smokers - by dr...

Fri, 30 Sep 2011 13:53:35 GMT

Dr Langkilde presents data on her 2011 publication in :Cancer Epidemiol Biomarkers Prev. Apr;20(4):609-18.
Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.
Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J.
Clinical Research Centre 136, Copenhagen University Hospital, Hvidovre, Denmark. annelangkilde@gmail.com
Abstract
BACKGROUND:
Soluble urokinase plasminogen activator receptor (suPAR) is a stable plasma biomarker associated with inflammation and disease. This study tested the association between suPAR levels and incident respiratory, gastrointestinal, or other types of cancer in initially cancer-free individuals from a general population-based prospective study.

METHODS:
Baseline plasma samples, baseline characteristics, and follow-up data were available from 2,656 individuals from the population-based Danish MONICA10 (MONItoring trends and determinants of CArdiovascular disease) study, followed for a median of 12.6 years. Cancer was diagnosed according to international classification of diseases (ICD) 8 and ICD-10 codes and suPAR levels were measured using a commercially available ELISA. The association of suPAR levels with incident cancer during follow-up was analyzed using Cox regression, adjusted for established risk factors and the inflammatory markers C-reactive protein (CRP) and leukocyte numbers.

RESULTS:
suPAR levels ranged from 0.6 to 22 ng/mL and median suPAR level was 4.01 ng/mL. An increase of 1 ng/mL in baseline suPAR was associated with adjusted HR of 1.61 (95% CI: 1.23-2.11, P < 0.001), 0.92 (95% CI: 0.69-1.24, P = 0.59), and 1.33 (95% CI: 1.13-1.58, P < 0.001) of being diagnosed with respiratory, gastrointestinal, and other cancer types, respectively.

CONCLUSION:
Elevated suPAR levels were associated with increased risk of incident respiratory cancer and other types of cancer, but not gastrointestinal cancers, independently of established risk factors, CRP, and leukocyte numbers.

IMPACT:
These findings suggest that inflammation is involved in cancer development. Risk algorithms based on established risk factors and risk-associated biomarkers should be developed and evaluated in large, general population-based studies. We suggest suPAR as a candidate for evaluation in cancer risk algorithms.

Case stories for the ICU - suPAR and prognosis by Prof Paradowski

Fri, 30 Sep 2011 13:41:35 GMT

Professor Marek T Paradowski from Veterans Central University Hospital in Lodz, Poland, studies the kinetics and prognostic ability of the biomarkers Procalcitonin (PCT), C-reactive Protein (CRP) and soluble urokinase receptor (suPAR). The talk was given at the 2nd suPAR symposium in Copenhagen 2011.

suPAR and HIV infection by Dr Ostrowski - Part 1

Fri, 30 Sep 2011 13:36:27 GMT

2´nd International suPAR Symposium

Wed, 24 Aug 2011 11:49:48 GMT

2’nd International suPAR Symposium
The 2nd International Conference on suPAR” was taking place in early spring 2011 at the Danish National Museum in Copenhagen.

The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.

The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.

The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will:

◦ Provide a forum to learn about new findings and current suPAR studies
◦ Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker
◦ Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements
◦ Facilitate foundation for international net-working

Preliminary Agenda

◦ Session 1: suPAR and 10-year risk in the General Population
◦ Session 2: suPAR and Prognosis in Infectious Diseases
◦ Session 3: suPAR as a Risk Biomarker in the Intensive Care Unit
◦ Session 4: Decreasing suPAR Concentration – Impact on survival?
◦ Session 5: Is there a Role for suPAR in Disease Risk Management?
◦